SciClone Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SciClone Pharmaceuticals, Inc. - overview
Established
1989
Location
Foster City, CA, US
Primary Industry
Pharmaceuticals
About
SciClone Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for advanced solid tumors, enhancing immune responses and potentially improving cancer therapy effectiveness. Founded in 1989 in Foster City, US, SciClone Pharmaceuticals, Inc. specializes in oncology therapeutics.
The company went public on the Hong Kong Stock Exchange on March 3, 2021, raising HKD 2039. 5 million through its IPO. The CEO is Friedhelm Blobel. SciClone Pharmaceuticals (Holdings) Limited specializes in the development and commercialization of innovative biopharmaceutical products, primarily targeting advanced solid tumors.
The company's flagship product, Zadaxin (Thymalfasin), is designed to enhance the immune response in cancer patients. It functions by modulating immune system activity, thereby potentially improving the efficacy of other cancer treatments. Through clinical trials, Zadaxin has been evaluated for various indications related to late-stage solid tumors, with its clinical research currently active in regions such as Asia and parts of Europe. The company's client base includes healthcare providers, hospitals, and oncology specialists who administer these therapies to patients in need of advanced cancer care.
SciClone Pharmaceuticals generated revenue of USD 160. 10 mn in 2016, with an EBITDA of USD 34. 22 mn. The company's revenue is derived through direct sales of its proprietary product, Zadaxin, to healthcare facilities and partnerships with distributors, ensuring market access.
Following its IPO in March 2021, where it raised HKD 2039. 5 million, SciClone Pharmaceuticals plans to invest in further product development and expand its market presence in Asia and Europe. The funds raised will support the launch of new products and enhance its clinical research capabilities.
Current Investors
IDG Capital, China Taiping Insurance Group, Shanghai Pharmaceuticals Holding
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.sciclone.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
SciClone Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | SciClone Pharmaceuticals, Inc. | - | ||||||||
| Public to Private | Completed | SciClone Pharmaceuticals, Inc. | - | ||||||||
| IPO | Completed | SciClone Pharmaceuticals, Inc. | - | ||||||||
| Buyout | Completed | SciClone Pharmaceuticals, Inc. | - | ||||||||
| Public to Private | Completed | SciClone Pharmaceuticals, Inc. | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.